These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11377082)

  • 1. Isolation of an unknown metabolite of the non-steroidal anti-inflammatory drug etodolac and its identification as 5-hydroxy etodolac.
    Strickmann DB; Blaschke G
    J Pharm Biomed Anal; 2001 Jul; 25(5-6):977-84. PubMed ID: 11377082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of the phase II metabolites of the non steroidal anti-inflammatory drug etodolac in human urine.
    Berendes U; Blaschke G
    Enantiomer; 1996; 1(4-6):415-22. PubMed ID: 9676278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separation and identification of etodolac and its urinary phase I metabolites using capillary electrochromatography and on-line capillary electrochromatography-electrospray ionisation mass spectrometry coupling.
    Strickmann DB; Chankvetadz B; Blaschke G; Desiderio C; Fanali S
    J Chromatogr A; 2000 Jul; 887(1-2):393-407. PubMed ID: 10961329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capillary electrochromatography-electrospray ionization mass spectrometry for the qualitative investigation of the drug etodolac and its metabolites in biological samples.
    Strickmann DB; Blaschke G
    J Chromatogr B Biomed Sci Appl; 2000 Oct; 748(1):213-9. PubMed ID: 11092600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etodolac in equine urine and serum: determination by high-performance liquid chromatography with ultraviolet detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry.
    Koupai-Abyazani MR; Esaw B; Laviolette B
    J Anal Toxicol; 1999; 23(3):200-9. PubMed ID: 10369330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug.
    Cunha PD; Lord RS; Johnson ST; Wilker PR; Aster RH; Bougie DW
    Transfusion; 2000 Jun; 40(6):663-8. PubMed ID: 10864985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel.
    Schepmann D; Blaschke G
    J Pharm Biomed Anal; 2001 Dec; 26(5-6):791-9. PubMed ID: 11600290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid.
    Sidelmann UG; Christiansen E; Krogh L; Cornett C; Tjørnelund J; Hansen SH
    Drug Metab Dispos; 1997 Jun; 25(6):725-31. PubMed ID: 9193874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of urinary metabolites of etodolac on diagnostic tests of bilirubin in urine.
    Sho Y; Ishiodori T; Oketani M; Kubozono O; Nakamura A; Takeuchi A; Morino A; Arima T
    Arzneimittelforschung; 1999 Jul; 49(7):572-6. PubMed ID: 10442203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent binding of etodolac acyl glucuronide to albumin in vitro.
    Smith PC; Song WQ; Rodriguez RJ
    Drug Metab Dispos; 1992; 20(6):962-5. PubMed ID: 1362954
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of the etodolac metabolite, 4-ureidoetodolac, in mouse, rat, dog, and man.
    Ferdinandi ES; Cochran D; Gedamke R
    Drug Metab Dispos; 1987; 15(6):921-4. PubMed ID: 2893722
    [No Abstract]   [Full Text] [Related]  

  • 12. Isolation and identification of the glucuronide of 4-(3H-1,2-dihydro-1-pyrrolizinone-2-methylamino)benzoic acid from rabbit urine.
    Dong Q; Gu J; Zhong D; Paul Fawcett J; Chu D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 772(2):369-72. PubMed ID: 12007782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolation and identification of a major metabolite of SFZ-47 in the rabbit urine].
    Dong QG; Gu JK; Zhong DF; Chu DF; Sun L
    Yao Xue Xue Bao; 2002 Feb; 37(2):141-3. PubMed ID: 12579962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the etodolac purity test by reversed phase high-performance liquid chromatography.
    Ammar A; Surmann P
    Pharmazie; 2008 Dec; 63(12):913-4. PubMed ID: 19177910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a high performance liquid chromatography-tandem mass spectrometry for the determination of etodolac in human plasma.
    Lee HS; Kang IM; Lee HW; Seo JH; Ryu JH; Choi SJ; Lee MJ; Jeong SY; Cho YW; Lee KT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Feb; 863(1):158-62. PubMed ID: 18218344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparative resolution of etodolac enantiomers by preferential crystallization method.
    Dung PT; Trung TQ; Kim KH
    Arch Pharm Res; 2009 Oct; 32(10):1425-31. PubMed ID: 19898806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective binding of etodolac to human serum albumin.
    Muller N; Lapicque F; Monot C; Payan E; Dropsy R; Netter P
    Chirality; 1992; 4(4):240-6. PubMed ID: 1389961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics.
    Ogiso T; Kitagawa T; Iwaki M; Tanino T
    Biol Pharm Bull; 1997 Apr; 20(4):405-10. PubMed ID: 9145219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling urinary metabolites of naproxen by liquid chromatography-electrospray mass spectrometry.
    Aresta A; Carbonara T; Palmisano F; Zambonin CG
    J Pharm Biomed Anal; 2006 Jun; 41(4):1312-6. PubMed ID: 16581219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.